FR2805993B1 - USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE - Google Patents

USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE

Info

Publication number
FR2805993B1
FR2805993B1 FR0002952A FR0002952A FR2805993B1 FR 2805993 B1 FR2805993 B1 FR 2805993B1 FR 0002952 A FR0002952 A FR 0002952A FR 0002952 A FR0002952 A FR 0002952A FR 2805993 B1 FR2805993 B1 FR 2805993B1
Authority
FR
France
Prior art keywords
niter
prevention
development
treatment
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0002952A
Other languages
French (fr)
Other versions
FR2805993A1 (en
Inventor
Rourke Stephen T O
Elizabeth Scalbert
Philippe Delagrange
Caroline Bennejean
Pierre Renard
Paul Vanhoutte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Priority to FR0002952A priority Critical patent/FR2805993B1/en
Publication of FR2805993A1 publication Critical patent/FR2805993A1/en
Application granted granted Critical
Publication of FR2805993B1 publication Critical patent/FR2805993B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0002952A 2000-03-08 2000-03-08 USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE Expired - Fee Related FR2805993B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0002952A FR2805993B1 (en) 2000-03-08 2000-03-08 USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0002952A FR2805993B1 (en) 2000-03-08 2000-03-08 USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE

Publications (2)

Publication Number Publication Date
FR2805993A1 FR2805993A1 (en) 2001-09-14
FR2805993B1 true FR2805993B1 (en) 2004-01-16

Family

ID=8847844

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0002952A Expired - Fee Related FR2805993B1 (en) 2000-03-08 2000-03-08 USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE

Country Status (1)

Country Link
FR (1) FR2805993B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096346B (en) * 2006-06-30 2010-12-15 瑟维尔实验室 New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725985B1 (en) * 1994-10-21 1996-11-15 Adir NOVEL TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2762598A1 (en) * 1997-04-25 1998-10-30 Adir NOVEL HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096346B (en) * 2006-06-30 2010-12-15 瑟维尔实验室 New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FR2805993A1 (en) 2001-09-14

Similar Documents

Publication Publication Date Title
MA26790A1 (en) DIETETIC OR PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF HYPER-OXALURIA
DE60044625D1 (en) Système d'assistance de conduire pour vehicules
MA26822A1 (en) COMPOUNDS FOR THE TREATMENT OF ISCHEMIA.
FR07C0046I2 (en) BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
MA26618A1 (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MALARIA
FR2710541B1 (en) Set for the introduction of a catheter.
FR2752819B1 (en) HOUSING FOR THE PACKAGING OF A SOLID OR SEMI-SOLID, DELITABLE PRODUCT
MA25823A1 (en) COMPOSITIONS FOR THE TREATMENT OF WATER.
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
OA09498A (en) "Use of baclofen for obtaining medicaments intended for the treatment of angina pectoris".
DZ3014A1 (en) Medicines for the treatment of hypertension.
DZ2316A1 (en) Pharmaceutical micro spheres of valproic acid for oral administration.
FR2809621B1 (en) USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES SUITABLE AS ANTIDIARRHOISTS
FR2795323B1 (en) USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE GASTROINTESTINAL SYSTEM
FR2733685B1 (en) USE OF BENZOPYRANE DERIVATIVES FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO THE C1- / HC03-, NA + INDEPENDENT EXCHANGER
MA26566A1 (en) USE OF KETOLIDES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR PREVENTING ARTERIAL THROMBOTIC COMPLICATIONS LINKED TO ATHEROSCLEROSIS.
FR2768346B1 (en) COMPOUND FOR INHIBITION OF PRESENILINE 1 FOR THE PREPARATION OF A MEDICAMENT AND DIAGNOSTIC AGENT
FR2805993B1 (en) USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF THE DEVELOPMENT OF NITER COMPOUND TOLERANCE
FR2716623B1 (en) Use of a tricyclic derivative for obtaining medicaments intended for the treatment of mnemo-cognitive disorders.
FR2751534B1 (en) COMPOSITION FOR IMPROVING ORAL HYGIENE
FR2714603B1 (en) Dermatological composition and its use for the preparation of a medicament.
FR2818150B1 (en) COMPOSITION FOR THE TREATMENT OF OBJECTS FOR DISINFECT
FR2828403B1 (en) USE OF HLA CLASS 1 SOLUBLE MOLECULES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL FOR INHIBITING ANGIOGENESIS
FR2732219B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MALARIA, BASED ON A MEMBER OF THE CHONDROITINE-GLYCOSAMINOGLYCAN FAMILY
FR2816214B1 (en) USE OF ANTAGONISTIC ESM-1 PROTEIN COMPOUND FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION AND / OR TREATMENT OF CANCER

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20051130